WHO welcomes report on efficacy of longer gaps between AstraZeneca doses

The fast-spreading delta variant is now dominating conversations about the virus, with vaccine efficacy measures, case counts and country lockdowns increasingly focused on it

Vaccine production
Agencies
1 min read Last Updated : Jul 03 2021 | 1:46 AM IST
A report from Oxford University saying that a longer gap between doses of AstraZeneca vaccines still provides protection is “very reassuring” for supply-strapped countries, World Health Organization chief scientist Soumya Swaminathan said.

Joachim Hombach, head of the WHO’s expert panel, said it was “great news” on spaced dosing for the vaccine, which would add flexibility to dosing schedules. The Oxford study released this week found that the second dose can be delayed up to 45 weeks and still lead to an enhanced immune response.

On the other hand, the head of the WHO, Tedros Adhanom Ghebreyesus, said the world is in “a very dangerous period” of the Covid-19 pandemic, noting the more contagious delta variant is identified in nearly 100 countries.

The fast-spreading delta variant is now dominating conversations about the virus, with vaccine efficacy measures, case counts and country lockdowns increasingly focused on it. South Korea’s case count reached the highest level in more than six months as the country begins to ease social distancing measures amid an accelerating vaccine rate.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Coronavirus VaccineWHO

Next Story